Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin production by engineered muscle cells.

L Gros1, E Riu, L Montoliu

  • 1Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain.

Human Gene Therapy
|May 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A case of successful surgical management of colonic duplication with pygomelia in a 2-month-old dog.

The Journal of small animal practice·2026
Same author

Correction: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.

Cell death and differentiation·2026
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

A myotropic AAV vector combined with skeletal muscle <i>cis</i>-regulatory elements improve glycogen clearance in mouse models of Pompe disease.

Molecular therapy. Methods & clinical development·2025
Same author

Bound-State Beta Decay of ^{205}Tl^{81+} Ions and the LOREX Project.

Physical review letters·2024
Same author

Lung cancer research and treatment: global perspectives and strategic calls to action.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Engineered muscle cells can produce and secrete mature insulin, offering a potential new therapy for Type 1 diabetes. This approach aims to provide a stable, basal level of insulin, improving glycemic control in diabetic patients.

Area of Science:

  • Biotechnology
  • Cell Therapy
  • Endocrinology

Background:

  • Type 1 diabetes management relies on insulin therapy, but current preparations struggle to maintain stable background insulin levels.
  • Achieving a consistent basal insulin profile is crucial for effective glycemic control.

Purpose of the Study:

  • To engineer muscle cells for continuous, long-term delivery of active human insulin.
  • To assess the feasibility of using genetically modified myotubes as a cell-based insulin replacement therapy.

Main Methods:

  • C2C12 mouse myoblast cells were stably transfected with a human proinsulin gene construct (MLC1/Insm).
  • Differentiated myotubes were analyzed for insulin production, processing, and secretion.
  • Biological activity of secreted insulin was confirmed through glucose uptake assays and gene expression studies.

Related Experiment Videos

  • Transplantation of engineered cells into diabetic mice was performed to evaluate in vivo efficacy.

    • Main Results:

    • Differentiated C2C12Insm myotube cells expressed high levels of insulin mRNA and protein.
    • Approximately 90% of proinsulin was processed to mature, biologically active insulin.
    • Cells secreted significant amounts of mature insulin (approx. 100 microU/10(6) cells/hr).
    • Transplanted cells led to increased insulin levels and reduced hyperglycemia in diabetic mice.

    Conclusions:

    • Engineered myotube cells can serve as a continuous source of biologically active insulin.
    • This cell-based approach shows promise for improving insulin replacement therapy in Type 1 diabetes.
    • Further development could lead to a more effective treatment strategy for managing diabetes.